参考文献/References:
[1] SIEGEL R L,MILLER K D,JEMAL A.Cancer statistics,2020[J].CA Cancer J Clin,2020,70(1):7-30.
[2] SUNG H,FERLAY J,SIEGEL R L,et al.Global cancer statistics 2020:GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J].CA Cancer J Clin,2021,71(3):209-249.
[3] TRAYES K P,COKENAKES S E H.Breast cancer treatment[J].Am Fam Physician,2021,104(2):171-178.
[4] KERR A J,DODWELL D,MCGALE P,et al.Adjuvant and neoadjuvant breast cancer treatments:a systematic review of their effects on mortality[J].Cancer Treat Rev,2022,105:102375.
[5] EMENS L A.Breast cancer immunotherapy:facts and hopes[J].Clin Cancer Res,2018,24(3):511-520.
[6] DE MELO GAGLIATO D,BUZAID A C,PEREZ-GARCIA J,et al.Immunotherapy in breast cancer:current practice and clinical challenges[J].BioDrugs,2020,34(5):611-623.
[7] CZERWI〖KG-\*3〗N〖DD(-\*2〗'SKA P,MAZUREK S,WIZNEROWICZ M.The complexity of TRIM28 contribution to cancer[J].J Biomed Sci,2017,24(1):63.
[8] CHIKUMA S,SUITA N,OKAZAKI I M,et al.TRIM28 prevents autoinflammatory T cell development in vivo[J].Nat Immunol,2012,13(6):596-603.
[9] CZERWINSKA P,JAWORSKA A M,WLODARCZYK N A,et al.Melanoma stem cell-like phenotype and significant suppression of immune response within a tumor are regulated by TRIM28 protein[J].Cancers,2020,12(10):2998.
[10] CZERWINSKA P,MACKIEWICZ A A.Low levels of TRIM28-interacting KRAB-ZNF genes associate with cancer stemness and predict poor prognosis of kidney renal clear cell carcinoma patients[J].Cancers,2021,13(19):4835.
[11] LIU J,HAN X,CHEN L,et al.TRIM28 is a distinct prognostic biomarker that worsens the tumor immune microenvironment in lung adenocarcinoma[J].Aging,2020,12(20):20308-20331.
[12] WEI C,CHENG J,ZHOU B,et al.Tripartite motif containing 28 (TRIM28) promotes breast cancer metastasis by stabilizing TWIST1 protein[J].Sci Rep,2016,6:29822.
[13] HAO L,LENG J,XIAO R,et al.Bioinformatics analysis of the prognostic value of Tripartite Motif 28 in breast cancer[J].Oncol Lett,2017,13(4):2670-2678.
[14] AZIZI E,CARR A J,PLITAS G,et al.Single-cell map of diverse immune phenotypes in the breast tumor microenvironment[J].Cell,2018,174(5):1293-1308.e36.
[15] GOFF S L,DANFORTH D N.The role of immune cells in breast tissue and immunotherapy for the treatment of breast cancer[J].Clin Breast Cancer,2021,21(1):e63-e73.
[16] 王璐,刘敏.乳腺癌患者血清中B7-同源物2和B7-同源物3的表达及临床意义[J].新乡医学院学报,2022,39(9):827-832,837.
WANG L,LIU M.Expression and clinical significance of B7 homolog 2 and B7 homolog 3 in serum of patients with breast cancer[J].J Xinxiang Med Univ,2022,39(9):827-832,837.
[17] 吴文章,张凡,贾祺,等.MAGE-A4在肿瘤诊断与免疫治疗中的作用研究进展[J].解放军医学杂志,2023,48(7):834-840.
WU W Z,ZHANG F,JIA Q,et al.Research progress on MAGE-A4 in tumor diagnosis and immunotherapy[J].Med J Chin PLA,2023,48(7):834-840.
[18] 刘逸贤,陈嵘,程忠平.免疫治疗在晚期或复发性子宫内膜癌中的应用进展[J].中华全科医学,2023,21(10):1753-1756,1797.
LIU Y X,CHEN R,CHENG Z P.Advances in immunotherapy in advanced or recurrent endometrial carcinoma[J].Chin J Gen Pract,2023,21(10):1753-1756,1797.
[19] YANG Y H,LIU J W,LU C,et al.CAR-T cell therapy for breast cancer:from basic research to clinical application[J].Int J Biol Sci,2022,18(6):2609-2626.
[20] ZHOU B,LIN W,LONG Y,et al.Notch signaling pathway:architecture,disease,and therapeutics[J].Signal Transduct Target Ther,2022,7(1):95.
[21] DE FRANCESCO E M,MAGGIOLINI M,MUSTI A M.Crosstalk between Notch,HIF-1α and GPER in breast cancer EMT[J].Int J Mol Sci,2018,19(7):E2011.
[22] EDWARDS A,BRENNAN K.Notch signalling in breast development and cancer[J].Front Cell Dev Biol,2021,9:692173.
[23] 鹿涛,高志棣.骨转移瘤的信号通路及中西医治疗研究进展[J].青岛大学学报(医学版),2022,58(4):628-632.
LU T,GAO Z D.Research advances in signaling pathways and integrated traditional Chinese and western medicine therapy for bone metastases[J].J Qingdao Univ Med Sci,2022,58(4):628-632.
[24] ABREU DE OLIVEIRA W A,LAITHY Y E,BRUNA A,et al.Wnt signaling in the breast:from development to disease[J].Front Cell Dev Biol,2022,10:884467.
[25] VAN SCHIE E H,VAN AMERONGEN R.Aberrant WNT/CTNNB1 signaling as a therapeutic target in human breast cancer:weighing the evidence[J].Front Cell Dev Biol,2020,8:25.
[26] AYYANAN A,CIVENNI G,CIARLONI L,et al.Increased Wnt signaling triggers oncogenic conversion of human breast epithelial cells by a Notch-dependent mechanism[J].Proc Natl Acad Sci U S A,2006,103(10):3799-3804.
[27] LING J,KUMAR R.Crosstalk between NFkB and glucocorticoid signaling:a potential target of breast cancer therapy[J].Cancer Lett,2012,322(2):119-126.
相似文献/References:
[1]张光谋,吴俊琢,徐振平,等.抗细胞凋亡基因bcl一2在乳腺癌中的表达[J].新乡医学院学报,2001,18(03):160.
[2]刘玉生 . 万里,李森恺.乳腺癌切除即期乳房再造[J].新乡医学院学报,2001,18(01):023.
[3]王承正,张锦瑜,邱树升,等.C—erbB一2与ER、PS一2在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[4]王承正,张锦瑜,邱树升,等.C2erbB22 与ER、PS22 在乳腺癌中的表达及其临床相关性[J].新乡医学院学报,2003,20(05):324.
[5]王志民,段西华,祁天义,等.多点皮瓣固定法预防乳腺癌术后皮下积液效果观察 [J].新乡医学院学报,2007,24(03):287.
[6]郭兰青.乳腺癌患者生活质量影响因素[J].新乡医学院学报,2008,25(06):637.
[7]曹兴玥,赵庆伟,靳艳,等.CD44和nm23在乳腺浸润性导管癌中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):042.
[8]靳艳,曹兴玥,赵庆伟,等.CD62P在人乳腺癌组织中的表达及其与淋巴结转移的关系[J].新乡医学院学报,2011,28(01):045.
[9]王 乐,王静萱,张清媛.乳腺癌骨转移靶向治疗进展[J].新乡医学院学报,2015,32(09):887.
[10]杨绍英,刘朝荣,张志刚,等.乳腺癌新辅助化学治疗前后雌激素受体、乳激素受体、Ki-67抗原和人类表皮生长因子受体-2的表达[J].新乡医学院学报,2017,34(2):125.[doi:10.7683/xxyxyxb.2017.02.012]
YANG Shao-ying,LIU Chao-rong,ZHANG Zhi-gang,et al.Expressions of estrogen receptor,progestin recetor,Ki-67 antigen,and human epidermal growth factor receptor 2 before and after neoadjuvant chemotherapy in patients with breast cancer[J].Journal of Xinxiang Medical University,2017,34(4):125.[doi:10.7683/xxyxyxb.2017.02.012]